We are a diversified healthcare group that is developing, investing in and delivering a range of exciting new technologies and leading edge medical devices that have the potential to make a real difference to the outcomes and quality of life of patients around the globe.Learn More
Long-term CardioCel study shows no evidence of calcification after 8 years
Admedus Limited (ASX: AHZ) has today announced positive long-term data from its Phase II extension study for the repair of congenital heart defects in paediatrics using CardioCel. All patients continue to progress well, with no sign of calcification after 8 years or need for repeat procedures. Read the full Company announcement here.
August 22nd 2016Find out more
Gardasil creator is testing a DNA vaccine to wipe out cancer-causing HPV virus
Professor Ian Frazer (the creator of Gardasil) is working with healthcare company Admedus to create a DNA vaccine which could be injected in people who already have HPV to stop it progressing to cervical cancer. Admedus Chief Scientific Officer Dr David Rhodes said the technology developed by Admedus in conjunction with Frazer could potentially be applied to a […]
March 3rd 2016Find out more
Admedus inks exclusive distro deal with Coroneo
Admedus (ASX:AHZ) has inked an exclusive distribution agreement with Coroneo to sell its extra aortic annuloplasty ring and other heart valve surgery instruments in Germany and the U.K.
January 27th 2016Find out more
CardioCel bio-scaffold launched and sold in Malaysia
CardioCel has now been launched in Malaysia and the Company has achieved its first sales in the country. Click here to read the full article
November 4th 2015Find out more